Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Altoona, Pennsylvania


Purpose:

This is a 24-week randomized, double-blind, multi-center, active-controlled (pioglitazone) study of tesaglitazar (0.5 mg and 1 mg) in patients with type 2 diabetes, not adequately controlled on diet and lifestyle advice alone during the run-in period. The study comprises a 3-week enrollment period, 6 week placebo single blind run in period followed by a 24-week double blind treatment period and a 3-week follow-up period.


Criteria:

Inclusion Criteria: - Provision of a written informed consent - Men or women who are ³18 years of age - Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control - Diagnosed with type 2 diabetes - Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents Exclusion Criteria: - Type 1 diabetes - New York Heart Association heart failure Class III or IV - Treatment with chronic insulin - History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) - History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells) - Creatinine levels above twice the normal range - Creatine kinase above 3 times the upper limit of normal - Received any investigational product in other clinical studies within 12 weeks - Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study


NCT ID:

NCT00214565


Primary Contact:

Study Director
AstraZeneca Galida Medical Science Director, MD
AstraZeneca


Backup Contact:

N/A


Location Contact:

Altoona, Pennsylvania
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.